Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its ...

Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.

Johnson & Johnson's immunology superstar Stelara and oncology blockbuster Darzalex have long been among the company's top ...

At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...

Biosimilar competition is expected in early January for the company’s second highest-selling drug, putting greater focus on ...

On a mission to collect a key Crohn’s disease approval and build out its inflammatory bowel disease (IBD) profile, Eli Lilly ...

Fresenius Kabi and Cellular Origins have announced a partnership to advance cell and gene therapy (CGT) by automating ...

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

Imuldosa is used for the treatment of patients with autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...

PRNewswire Ahmedabad Gujarat [India] October 14 Accord BioPharma Inc the US specialty division of Intas Pharmaceuticals Ltd ...